A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 75
- Population
- ALL · 40 Years to 80 Years
- Duration
- 2020-01-06 to 2023-02-01
- Intervention
- Fisetin; Placebo oral capsule
- Comparator
- Placebo
- Outcomes measured
- Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — Duration of study, an average of 12…; Change in Levels of Pro-inflammatory Markers Associated With Senescence — 14 days, 45 days, 6 months, 12 months (post 1…; Change in Levels of Cartilage Degenerating Markers Associated With OA — 14 days, 45 days, 6 months, 12 months (post 1st…; Change in Physical Function of the Study Knee (6 Min Walk) — 6 months, and 12 months (post 1st drug dose); Change in Physical Function of the Study Knee (Timed-up-and-go Test) — 6 months, and 12 months (post 1st drug dose); Change in Physical Function of the Study Knee (Fast 4-meter Walk) — 6 months, and 12 months (post 1st drug dose); Change in Physical Function of the Study Knee (LEK) — 6 months, and 12 months (post 1st drug dose); Change in Physical Function of the Study Knee (Stair-Climbing Test) — 6 months, and 12 months (post 1st drug dose); Change in Muscle Strength (Isokinetic Dynamometry) — 6 months, and 12 months (post 1st drug dose); Evaluation of Patient Reported Outcomes (PROs) for Knee Pain — every 3 days for the first 6-weeks of drug dosing, then…; Evaluation of Patient Reported Outcomes (PROs) for Knee Function — 6 months, 12 months, and 18 months (post 1st drug do…; Change in the Quality of Articular Cartilage in the Study Knee With Quantitative Magnetic Resonance Imaging (MRI) — 6 m…; Number of Participants Who Convert to Alterative Treatment Within Each Group. — Any time during 18-month monitoring per…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Senolytics · 60%Title contains controlled topic terminology.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.